A Phase 3 Open-label, Multicenter, Randomized Study of A

Project: Research project

Project Details

Description

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation
StatusActive
Effective start/end date8/1/151/31/21

Funding

  • ASTELLAS PHARMA, INC.

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.